F7: Coagulation factor VII
Initiates the extrinsic pathway of blood coagulation.
- Drugs that act on it: 6
- Approved: 3
- In phases 1 to 3: 3
- Sponsors: 5
Who is on it, and how far along
Every drug ChEMBL records acting on F7, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
- Protein or peptide 3
- Other 2
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- AbbVie117%
- Novo Nordisk117%
- Pfizer117%
- Roche117%
- Shanghai RAAS Blood Products Co., Ltd.117%
| Coagulation factor vii human | Approved | Shanghai RAAS Blood Products Co., Ltd. | Protein or peptide | Exogenous protein | 4 |
| Eptacog alfa (activated) | Approved | Roche | Protein or peptide | Exogenous protein | 4 |
| Eptacog beta (activated) | Approved | — | Other | Exogenous protein | 0 |
| Prothrombin complex concentrate | Phase 3 | Pfizer | Protein or peptide | Exogenous protein | 32 |
| Eptacog alfa pegol (activated) | Phase 2 | Novo Nordisk | Other | Exogenous protein | 0 |
| PCI-27483 | Phase 2 | AbbVie | Small molecule | InhibitorCoagulation factor VII inhibitor | 0 |
| A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without Inhibitors | Prothrombin complex concentrate | Phase 3 | Recruiting | Pfizer | Nov 9, 2026 |
| A Study to Describe Patient REal-world FitusiRan ExpeRience | Prothrombin complex concentrate | — | Not yet recruiting | Sanofi | Oct 26, 2026 |
| Prothrombin Complex Concentrate (PCC) | Prothrombin complex concentrate | Phase 4 | Not yet recruiting | University of Miami | Oct 19, 2026 |
| Very Low-volume Plasma Exchange in ACLF | Prothrombin complex concentrate | Not applicable | Not yet recruiting | Third Affiliated Hospital, Sun Yat-Sen University | Oct 5, 2026 |
| A Phase II Exploratory Study of SR604 Injection Evaluating the Safety and Efficacy in the Treatment of Congenital Coagulation Factor VII Deficiency | Coagulation factor vii human | Phase 2 | Not yet recruiting | Shanghai RAAS Blood Products Co., Ltd. | Jul 17, 2026 |
| PCC Treatment for Hemophilia Patients With Inhibitor(2022PCC-A) | Prothrombin complex concentrate | Phase 4 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | Feb 12, 2026 |
| A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency | Coagulation factor vii human | Phase 2 | Recruiting | Hemab ApS | Jan 16, 2026 |
| Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB) | Prothrombin complex concentrate | Phase 3 | Recruiting | CSL Behring | Jul 30, 2025 |
| An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment | Eptacog alfa (activated), Prothrombin complex concentrate | — | Active, not recruiting | Hoffmann-La Roche | Mar 19, 2025 |
| Efficacy and Safety Study of Urapidil Alone or With Esmolol in Treating Acute Hypertensive Intracerebral Hemorrhage | Prothrombin complex concentrate | — | Not yet recruiting | Qianfoshan Hospital | Oct 10, 2024 |
| SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors | Coagulation factor vii human, Eptacog alfa (activated) | Phase 4 | Recruiting | American Thrombosis and Hemostasis Network | Nov 30, 2020 |
| Treatment of Hemophilia A Patients With FVIII Inhibitors | Coagulation factor vii human, Eptacog alfa (activated) | — | Recruiting | Emory University | Jul 17, 2019 |
| Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial | Eptacog alfa (activated) | Phase 3 | Active, not recruiting | Joseph Broderick, MD | Apr 12, 2018 |
- Factor VII deficiency0.85
- Congenital factor VII deficiency0.78
- Hemophilia A0.56
- Hemophilia B0.55
- Blood coagulation disease0.55
- Abnormality of coagulation0.44
- Coagulation protein disease0.41
- Abnormal bleeding0.40
- Glanzmann thrombasthenia 10.38
- Intracerebral hemorrhage0.37
- Glaucoma0.37
- Open-angle glaucoma0.37
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3991, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P08709, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets